A MULTICENTER, OPEN-LABEL CONTINUATION TRIAL EVALUATING THE TOLERABILITY AND ACTIVITY OF DEPSIPEPTIDE (FK228) IN PATIENTS THAT HAVE COMPLETED A PRIOR CLINICAL STUDY WITH DEPSIPEPTIDE

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000469-13

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of this trial is to evaluate the safety and tolerability of extended treatment with depsipeptide in patients who have at least demonstrated stable disease on a prior Gloucester-sponsored depsipeptide clinical trial, and in the opinion of their physician/investigator might benefit from continued treatment with depsipeptide.


Critère d'inclusion

  • Refractory Prostate cancer

Liens